Ernie Riffer

Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults

Sam Jackson, Joseph R. Lentino, James Kopp et al. · Vaccine · 2017 · 185 citations · Full text

Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial

John H. Beigel, Yajing Bao, Joy Beeler et al. · The Lancet Infectious Diseases · 2017 · 94 citations · Full text

Antiviral Drug Development, Antiviral Therapy, Virology +5

Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial

Karin Hardt, An Vandebosch, Jerald Sadoff et al. · The Lancet Infectious Diseases · 2022 · 84 citations · Full text

Vaccination, Vaccine Safety, Vaccine Development +7

Comparison of once-daily extended-release ciprofloxacin and conventional twice-daily ciprofloxacin for the treatment of uncomplicated urinary tract infection in women

Dan Henry, Robert Bettis, Ernie Riffer et al. · Clinical Therapeutics · 2002 · 65 citations

Urology, Antimicrobial Stewardship, Antibiotics +5

A controlled, double-blind, multicenter study comparing clarithromycin extended-release tablets and levofloxacin tablets in the treatment of community-acquired pneumonia

Mark H. Gotfried, Dan Dattani, Ernie Riffer et al. · Clinical Therapeutics · 2002 · 50 citations

Community-acquired Pneumonia, Antibiotics, Antimicrobial Stewardship +9